Short Interest in Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Decreases By 73.8%

Key Points

• Short interest in Daiichi Sankyo Co., Ltd. decreased by 73.8% in September, dropping from 33,600 shares to 8,800 shares as of September 30th.
• The company's shares are trading at $26.90, with a market capitalization of $50.96 billion and a P/E ratio of 25.38.
• Daiichi Sankyo specializes in developing pharmaceutical products, including innovative treatments for conditions like anemia and certain types of cancer.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - ) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totaling 8,800 shares, a decrease of 73.8% from the September 15th total of 33,600 shares. Based on an average daily trading volume, of 519,400 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 519,400 shares, the days-to-cover ratio is currently 0.0 days.

Daiichi Sankyo Trading Down 0.3%

Shares of DSNKY traded down $0.07 during mid-day trading on Friday, hitting $26.90. 97,801 shares of the company's stock traded hands, compared to its average volume of 266,356. The firm has a market capitalization of $50.96 billion and a P/E ratio of 25.38. The business's 50-day moving average price is $24.72 and its 200-day moving average price is $24.32. Daiichi Sankyo has a 1 year low of $20.92 and a 1 year high of $34.19. The company has a quick ratio of 1.60, a current ratio of 2.31 and a debt-to-equity ratio of 0.06.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.